Though it conferred a significant improvement in survival without increasing toxicity, high-dose thoracic radiotherapy should not be the new...
Data suggest fewer people are dying from stomach cancer, but in some countries, the risk of colorectal cancer death is increasing or declining...
Lorlatinib bested crizotinib as first-line therapy for ALK-positive non–small cell lung cancer.
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Dr. Alan Lyss reviews a panel discussion about how COVID-19 has affected cancer research.
The Veterans Health Administration has launched initiatives to screen potential patients, to evaluate optimal treatment for participants with...
Among patients with a MET exon 14 skipping mutation, capmatinib produced a response in 41% of previously treated patients and 68% of treatment-...